Azabicyclic compounds for the treatment of disease
申请人:——
公开号:US20030232853A1
公开(公告)日:2003-12-18
The invention provides compounds of Formula I:
1
wherein Azabicyclo is
2
These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which &agr;7 is known to be involved.
[EN] AZABICYCLOOCTAN-3-ONE DERIVATIVES AND USE THEREOF<br/>[FR] DERIVE D'AZABICYCLOOCTANE-3-ONE ET UTILISATION CORRESPONDANTE
申请人:APREA AB
公开号:WO2005090341A1
公开(公告)日:2005-09-29
Compounds of Formula (I) processes for preparing them, pharmaceutical compositions comprising them. The use of compounds of formula (I) for hyperproliferative diseases, e.g. cancer as well as autoimmune diseases and heart diseases.
[EN] 1H-PYRAZOLE AND 1H-PYRROLE-AZABICYCLIC COMPOUNDS WITH ALFA-7 NACHR ACTIVITY<br/>[FR] COMPOSES AZABICYCLIQUE DE 1H-PYRAZOLE ET 1H-PYRROLE SERVANT A EFFECTUER UN TRAITEMENT THERAPEUTIQUE
申请人:UPJOHN CO
公开号:WO2004013137A1
公开(公告)日:2004-02-12
The invention provides compounds of Formula (I), wherein Azabicyclo is Formula (I, II, III, IV, V, VI, VII); W is Formula (m); where the variables have the definitions discussed herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat a disease or condition in which α7 is known to be involved.
这项发明提供了Formula (I)的化合物,其中Azabicyclo是Formula (I, II, III, IV, V, VI, VII); W是Formula (m); 其中变量的定义如本文所述。这些化合物可以是药用盐或组合物的形式,可以是纯对映体形式或混合物,对于治疗已知涉及α7的疾病或症状的药物具有用处。
Towards benign syntheses of bipyridines: versatile approach to supramolecular building blocks
作者:Gareth W.V. Cave、Colin L. Raston
DOI:10.1016/j.tetlet.2005.02.081
日期:2005.4
Chiral and achiral bipyridines are readily accessible via a solvent-free Michael addition involving solid NaOH, followed by treatment with ammonium acetate in acetic acid, as a ‘onepot’ more benign protocol, affording pure products in high yield, typically >80%.
Compounds of Formula (1) process for preparing them, pharmaceutical compositions comprising them. The use of compounds of formula (1) for hyperproliferative diseases, e.g. cancer as well as autoimmune diseases and heart disease.